Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUV2208A in CLDN18.2-Positive Advanced Solid Tumors
NCT07680257Phase 1Recruiting
- Sponsor
- Celest Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of SUV2208A in solid tumor (3 arms), sponsored by Celest Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 24 days and Adverse Events and Serious Adverse Events at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
SUV2208A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07680257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680257.